- Home
- TRU vs RPRX Comparison
TRU vs RPRX Comparison
Compare TRU & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRU | RPRX |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.5B | 16.2B |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRU | RPRX |
|---|---|---|
| Price | $84.48 | $39.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $104.45 | $46.00 |
| AVG Volume (30 Days) | 1.7M | ★ 4.3M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | 0.54% | ★ 2.21% |
| EPS Growth | ★ 87.22 | N/A |
| EPS | ★ 2.14 | 1.75 |
| Revenue | ★ $4,441,800,000.00 | $2,349,844,000.00 |
| Revenue This Year | $9.59 | $37.13 |
| Revenue Next Year | $7.57 | $1.48 |
| P/E Ratio | $39.48 | ★ $22.68 |
| Revenue Growth | ★ 8.30 | 3.70 |
| 52 Week Low | $66.38 | $24.05 |
| 52 Week High | $101.42 | $41.24 |
Technical Indicators
Market Signals| Indicator | TRU | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 57.50 |
| Support Level | $82.16 | $39.24 |
| Resistance Level | $85.61 | $40.50 |
| Average True Range (ATR) | 2.10 | 0.91 |
| MACD | 0.21 | -0.08 |
| Stochastic Oscillator | 79.89 | 76.02 |
Price Performance
Historical ComparisonAbout TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.